OBJECTIVE: We evaluated patients with fragile X-associated tremor/ataxia syndrome (FXTAS), a neurodegenerative disorder associated with a CGG repeat expansion in the premutation range in the fragile X mental retardation 1 (FMR1) gene. METHODS: Neurological, psychiatric and neuropsychological evaluations were performed on 15 male patients with FXTAS. RESULTS: Seven cases were diagnosed with dementia, and seven others were diagnosed with mood and/or anxiety disorders. Twelve subjects demonstrated deficits on neuropsychological testing. CONCLUSIONS: Physicians assessing dementia patients are urged to consider this newly described syndrome, especially in patients with dementia associated with a movement disorder and in those with a family history of mental retardation. If FXTAS is a possible diagnosis, physicians may carry out FMR1 DNA testing; patients who test positive on DNA testing should undergo magnetic resonance imaging, be referred to neurology and receive genetic counseling.
OBJECTIVE: We evaluated patients with fragile X-associated tremor/ataxia syndrome (FXTAS), a neurodegenerative disorder associated with a CGG repeat expansion in the premutation range in the fragile X mental retardation 1 (FMR1) gene. METHODS: Neurological, psychiatric and neuropsychological evaluations were performed on 15 male patients with FXTAS. RESULTS: Seven cases were diagnosed with dementia, and seven others were diagnosed with mood and/or anxiety disorders. Twelve subjects demonstrated deficits on neuropsychological testing. CONCLUSIONS: Physicians assessing dementiapatients are urged to consider this newly described syndrome, especially in patients with dementia associated with a movement disorder and in those with a family history of mental retardation. If FXTAS is a possible diagnosis, physicians may carry out FMR1 DNA testing; patients who test positive on DNA testing should undergo magnetic resonance imaging, be referred to neurology and receive genetic counseling.
Authors: David Hessl; Flora Tassone; Danuta Z Loesch; Elizabeth Berry-Kravis; Maureen A Leehey; Louise W Gane; Ingrid Barbato; Cathlin Rice; Emma Gould; Deborah A Hall; James Grigsby; Jacob A Wegelin; Susan Harris; Foster Lewin; Dahlia Weinberg; Paul J Hagerman; Randi J Hagerman Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2005-11-05 Impact factor: 3.568
Authors: Elizabeth Berry-Kravis; Kristina Potanos; Dahlia Weinberg; Lili Zhou; Christopher G Goetz Journal: Ann Neurol Date: 2005-01 Impact factor: 10.422
Authors: James A Bourgeois; Sarah M Coffey; Susan M Rivera; David Hessl; Louise W Gane; Flora Tassone; Claudia Greco; Brenda Finucane; Lawrence Nelson; Elizabeth Berry-Kravis; Jim Grigsby; Paul J Hagerman; Randi J Hagerman Journal: J Clin Psychiatry Date: 2009-05-05 Impact factor: 4.384
Authors: Jim Grigsby; Angela G Brega; Rachael E Bennett; James A Bourgeois; Andreea L Seritan; Glenn K Goodrich; Randi J Hagerman Journal: Clin Neuropsychol Date: 2016-06-29 Impact factor: 3.535
Authors: Andreea L Seritan; Andrea Schneider; John M Olichney; Maureen A Leehey; R Scott Akins; Randi J Hagerman Journal: Am J Med Genet A Date: 2009-11 Impact factor: 2.802
Authors: Andreea L Seritan; Danh V Nguyen; Sarah Tomaszewski Farias; Ladson Hinton; Jim Grigsby; James A Bourgeois; Randi J Hagerman Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2008-10-05 Impact factor: 3.568